Leal Reis, I.; Lopes, B.; Sousa, P.; Sousa, A.C.; Branquinho, M.; Caseiro, A.R.; Pedrosa, S.S.; Rêma, A.; Oliveira, C.; Porto, B.; Atayde, L.; Amorim, I.; Alvites, R.; Santos, J.M.; Maurício, A.C. Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies—Proof of Concept. Animals2023, 13, 1312.
Leal Reis, I.; Lopes, B.; Sousa, P.; Sousa, A.C.; Branquinho, M.; Caseiro, A.R.; Pedrosa, S.S.; Rêma, A.; Oliveira, C.; Porto, B.; Atayde, L.; Amorim, I.; Alvites, R.; Santos, J.M.; Maurício, A.C. Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies—Proof of Concept. Animals 2023, 13, 1312.
Leal Reis, I.; Lopes, B.; Sousa, P.; Sousa, A.C.; Branquinho, M.; Caseiro, A.R.; Pedrosa, S.S.; Rêma, A.; Oliveira, C.; Porto, B.; Atayde, L.; Amorim, I.; Alvites, R.; Santos, J.M.; Maurício, A.C. Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies—Proof of Concept. Animals2023, 13, 1312.
Leal Reis, I.; Lopes, B.; Sousa, P.; Sousa, A.C.; Branquinho, M.; Caseiro, A.R.; Pedrosa, S.S.; Rêma, A.; Oliveira, C.; Porto, B.; Atayde, L.; Amorim, I.; Alvites, R.; Santos, J.M.; Maurício, A.C. Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies—Proof of Concept. Animals 2023, 13, 1312.
Abstract
Tendons and ligaments injuries are frequent in sport horses and humans, representing a great therapeutic challenge. Tissue regeneration and function recovery are the paramount of tendon and ligament lesions management. Nowadays, several regenerative treatments are being developed, based on the use of stem cell and stem cell-based therapies. In the present study, the preparation of equine synovial membrane mesenchymal stem cells (eSM-MSCs) for clinical use - collection, transport, isolation, differentiation, characterization, and application is described. These cells are fibroblast-like and grow in clusters. They retain an osteogenic, chondrogenic and adipogenic differentiation potential. 16 clinical cases of tendonitis and desmitis, treated with allogenic eSM-MSCs and autologous serum are also presented, including their evaluation, treatment and follow-up. The use of autologous serum as a vehicle concern to a decreased immunogenic response after the administration of this combination and to its healing properties, due to the presence of growth factors and immunoglobulins. Most of the cases (14/16), healed in 30 days and presented a good outcome. Treatment of tendon and ligament lesions with the mixture of eSM-MSCs and autologous serum appears to be a promising clinical option for this category of lesions in equine patients.
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.